https://novapharmanews.com/us/news/trump-administration-strips-job-protections-nih-officials-pharma-impact 2026-06-04T17:53:04.860Z NovaPharmaNews en 2026-06-04T07:08:57.385Z Trump Administration Strips Job Protections of Top NIH Officials: What Pharma Teams Must Know https://novapharmanews.com/uploads/articles/trump-administration-strips-job-protections-nih-officials-pharma-impact.webp Trump Administration Strips Job Protections of Top NIH Officials: What Pharma Teams Must Know https://novapharmanews.com/apac/news/nmpa-drug-approvals-2025-record-first-global-approvals 2026-06-04T15:42:21.900Z NovaPharmaNews en 2026-06-04T03:21:58.215Z NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access https://novapharmanews.com/uploads/articles/nmpa-drug-approvals-2025-record-first-global-approvals.webp NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access https://novapharmanews.com/eu/news/ema-ama-african-regulators-ebola-clinical-trials-2026 2026-06-04T14:58:54.181Z NovaPharmaNews en 2026-06-04T03:00:14.543Z EMA, AMA and African Regulators Unite to Accelerate Ebola Clinical Trials Ebola https://novapharmanews.com/uploads/articles/ema-ama-african-regulators-ebola-clinical-trials-2026.webp EMA, AMA and African Regulators Unite to Accelerate Ebola Clinical Trials https://novapharmanews.com/us/news/astrazeneca-daiichi-drug-approval-breast-cancer 2026-06-04T04:14:31.417Z NovaPharmaNews en 2026-06-04T02:48:21.704Z AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma breast cancer, triple-negative breast cancer https://novapharmanews.com/uploads/articles/astrazeneca-daiichi-drug-approval-breast-cancer.webp AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma https://novapharmanews.com/us/news/fda-flashback-breast-cancer-april-2026 2026-06-04T16:17:09.390Z NovaPharmaNews en 2026-06-04T02:48:21.704Z FDA Flashback: Key Breast Cancer Decisions from April 2026 breast cancer https://novapharmanews.com/uploads/articles/fda-flashback-breast-cancer-april-2026.webp FDA Flashback: Key Breast Cancer Decisions from April 2026 https://novapharmanews.com/eu/news/chmp-negative-stance-acadia-rett-syndrome-drug 2026-06-04T17:32:33.343Z NovaPharmaNews en 2026-06-04T02:48:21.704Z CHMP Negative Opinion on Acadia's Rett Syndrome Drug: Implications for Investors and Pharma Teams Rett syndrome https://novapharmanews.com/uploads/articles/chmp-negative-stance-acadia-rett-syndrome-drug.webp CHMP Negative Opinion on Acadia's Rett Syndrome Drug: Implications for Investors and Pharma Teams https://novapharmanews.com/eu/news/who-europe-access-novel-medicines 2026-06-04T10:09:12.934Z NovaPharmaNews en 2026-06-04T02:48:21.704Z WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma https://novapharmanews.com/uploads/articles/who-europe-access-novel-medicines.webp WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma https://novapharmanews.com/eu/news/owkin-astrazeneca-ai-collaboration-drug-research 2026-06-04T14:43:25.768Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Owkin and AstraZeneca Enhance AI Collaboration for Drug Research https://novapharmanews.com/uploads/articles/owkin-astrazeneca-ai-collaboration-drug-research.webp Owkin and AstraZeneca Enhance AI Collaboration for Drug Research https://novapharmanews.com/eu/news/hayes-esmo-breast-cancer-award-2026 2026-06-04T08:12:54.982Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights breast cancer https://novapharmanews.com/uploads/articles/hayes-esmo-breast-cancer-award-2026.webp Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights https://novapharmanews.com/eu/news/esmo-asia-nadia-harbeck-oncology-advances 2026-06-04T12:05:40.848Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Insights from ESMO Asia: Nadia Harbeck on Oncology Advances oncology https://novapharmanews.com/uploads/articles/esmo-asia-nadia-harbeck-oncology-advances.webp Insights from ESMO Asia: Nadia Harbeck on Oncology Advances https://novapharmanews.com/apac/news/cell-gene-therapy-approvals-china-regulatory-updates 2026-06-04T15:42:23.534Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Cell and Gene Therapy Approvals in China: Latest Regulatory Updates gene therapy https://novapharmanews.com/uploads/articles/cell-gene-therapy-approvals-china-regulatory-updates.webp Cell and Gene Therapy Approvals in China: Latest Regulatory Updates https://novapharmanews.com/us/news/pharma-in-focus-regulatory-updates 2026-06-04T18:10:55.467Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Pharma in Focus: Regulatory Updates You Need to Know https://novapharmanews.com/uploads/articles/pharma-in-focus-regulatory-updates.webp Pharma in Focus: Regulatory Updates You Need to Know https://novapharmanews.com/us/news/fierce-biotech-week-2026-recap 2026-06-04T17:44:37.824Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Fierce Biotech Week 2026: Key Insights and Highlights https://novapharmanews.com/uploads/articles/fierce-biotech-week-2026-recap.webp Fierce Biotech Week 2026: Key Insights and Highlights https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-06-04T12:33:59.440Z NovaPharmaNews en 2026-06-04T02:48:21.704Z CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/uploads/articles/chmp-may-2026-output-shift-european-drug-development.webp CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/apac/news/decade-ai-medical-device-regulation-2015-2025 2026-06-04T15:42:23.195Z NovaPharmaNews en 2026-06-04T02:48:21.704Z A Decade of AI Medical Device Regulation: Key Updates for Pharma https://novapharmanews.com/uploads/articles/decade-ai-medical-device-regulation-2015-2025.webp A Decade of AI Medical Device Regulation: Key Updates for Pharma https://novapharmanews.com/eu/news/eu-commission-advances-critical-medicines-act 2026-06-04T12:38:13.357Z NovaPharmaNews en 2026-06-04T02:48:21.704Z EU Commission Advances Critical Medicines Act: Market Implications https://novapharmanews.com/uploads/articles/eu-commission-advances-critical-medicines-act.webp EU Commission Advances Critical Medicines Act: Market Implications https://novapharmanews.com/eu/news/cancer-therapy-ost-her2-2026-ema-call 2026-06-04T17:52:25.022Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data OST-HER2, cancer https://novapharmanews.com/uploads/articles/cancer-therapy-ost-her2-2026-ema-call.webp Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data https://novapharmanews.com/apac/news/smarter-medical-devices-ecosystem-india-regulatory-updates 2026-06-04T17:38:39.575Z NovaPharmaNews en 2026-06-04T02:48:21.704Z Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates healthcare technologies, medical devices https://novapharmanews.com/uploads/articles/smarter-medical-devices-ecosystem-india-regulatory-updates.webp Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates https://novapharmanews.com/us/news/fda-approves-first-oral-covid-19-pep-drug-xocova 2026-06-04T12:35:34.982Z NovaPharmaNews en 2026-06-04T01:54:35.580Z FDA Approves First Oral COVID-19 PEP Drug, Xocova XOCOVA, ensitrelvir, Veklury, remdesivir, COVID-19 https://novapharmanews.com/uploads/articles/fda-approves-first-oral-covid-19-pep-drug-xocova.webp FDA Approves First Oral COVID-19 PEP Drug, Xocova https://novapharmanews.com/us/news/legend-biotech-in-vivo-car-t-lymphoma-data-surge 2026-06-04T18:10:53.737Z NovaPharmaNews en 2026-06-04T01:03:07.735Z Legend Biotech surges on early in vivo CAR-T data for lymphoma Kymriah, in vivo CAR-T, cell therapy, lymphoma, blood cancer https://novapharmanews.com/uploads/articles/legend-biotech-in-vivo-car-t-lymphoma-data-surge.webp Legend Biotech surges on early in vivo CAR-T data for lymphoma https://novapharmanews.com/us/news/halomd-lawsuit-update-highmark-health-no-surprises-act 2026-06-04T18:12:25.696Z NovaPharmaNews en 2026-06-03T23:40:28.314Z HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute https://novapharmanews.com/uploads/articles/halomd-lawsuit-update-highmark-health-no-surprises-act.webp HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-18-may-2026 2026-06-04T02:55:42.914Z NovaPharmaNews en 2026-06-03T19:23:49.735Z Regulatory Round-Up: Key Drug Approvals on May 18, 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-18-may-2026.webp Regulatory Round-Up: Key Drug Approvals on May 18, 2026 https://novapharmanews.com/eu/news/us-europe-biosimilar-approvals-2026 2026-06-04T17:42:28.245Z NovaPharmaNews en 2026-06-03T19:10:52.379Z Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD https://novapharmanews.com/uploads/articles/us-europe-biosimilar-approvals-2026.webp Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD https://novapharmanews.com/eu/news/key-cancer-drugs-esmo-2025 2026-06-04T04:14:40.921Z NovaPharmaNews en 2026-06-03T19:05:29.875Z Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights cancer https://novapharmanews.com/uploads/articles/key-cancer-drugs-esmo-2025.webp Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights https://novapharmanews.com/us/news/stat-trump-s-medicaid-work-requirements-have-an-unwelcome-surprise-for-some-states-and-patients 2026-06-04T12:37:53.937Z NovaPharmaNews en 2026-06-03T18:49:07.382Z STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients https://novapharmanews.com/uploads/articles/stat-trump-s-medicaid-work-requirements-have-an-unwelcome-surprise-for-some-states-and-patients.webp STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients https://novapharmanews.com/us/news/military-eating-disorders-prevalence-impact 2026-06-04T11:57:00.421Z NovaPharmaNews en 2026-06-03T18:49:06.601Z The Military's Role in the Rising Tide of Eating Disorders eating disorders https://novapharmanews.com/uploads/articles/military-eating-disorders-prevalence-impact.webp The Military's Role in the Rising Tide of Eating Disorders https://novapharmanews.com/eu/news/european-navenibart-deal-biocryst-analysis 2026-06-04T04:14:53.936Z NovaPharmaNews en 2026-06-03T18:10:13.708Z European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio Navenibart, rare disease https://novapharmanews.com/uploads/articles/european-navenibart-deal-biocryst-analysis.webp European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio https://novapharmanews.com/apac/news/risen-pharma-phase-2-trial-rp902-alzheimers 2026-06-04T04:14:57.938Z NovaPharmaNews en 2026-06-03T18:00:50.146Z Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's RP902, Alzheimer's disease, Mild Cognitive Impairment https://novapharmanews.com/uploads/articles/risen-pharma-initiates-phase-2-trial-for-rp902-in-alzheimer-s.webp Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's https://novapharmanews.com/us/news/fda-blueprint-regulatory-risk-animal-testing-alternatives 2026-06-04T13:36:29.344Z NovaPharmaNews en 2026-06-03T17:42:14.685Z FDA Blueprint Aims to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/uploads/articles/fda-blueprint-regulatory-risk-animal-testing-alternatives.webp FDA Blueprint Aims to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/apac/news/regulatory-updates-optical-coherence-tomography-pharma 2026-06-04T08:09:00.601Z NovaPharmaNews en 2026-06-03T17:18:44.483Z Optical Coherence Tomography Gains Regulatory Traction in Pharma Filings https://novapharmanews.com/uploads/articles/regulatory-updates-optical-coherence-tomography-pharma.webp Optical Coherence Tomography Gains Regulatory Traction in Pharma Filings https://novapharmanews.com/us/news/china-drug-development-oncology-us 2026-06-04T17:49:28.820Z NovaPharmaNews en 2026-06-03T17:07:37.783Z China’s Rise in Drug Development Looms Over U.S. Oncology Market oncology, lung cancer https://novapharmanews.com/uploads/articles/china-s-rise-in-drug-development-looms-over-u-s-oncology-market.webp China’s Rise in Drug Development Looms Over U.S. Oncology Market https://novapharmanews.com/eu/news/horizon-scanning-ema-regulatory-updates 2026-06-04T17:12:25.543Z NovaPharmaNews en 2026-06-03T16:59:25.064Z EMA Horizon Scanning: Navigating Regulatory Updates for Future Medicines https://novapharmanews.com/uploads/articles/horizon-scanning-ema-regulatory-updates.webp EMA Horizon Scanning: Navigating Regulatory Updates for Future Medicines https://novapharmanews.com/apac/news/datroway-approved-metastatic-tnbc 2026-06-04T10:22:15.001Z NovaPharmaNews en 2026-06-03T16:51:22.911Z Datroway Approved: A New Hope for Metastatic TNBC Patients Datroway, metastatic TNBC, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-approved-metastatic-tnbc.webp Datroway Approved: A New Hope for Metastatic TNBC Patients https://novapharmanews.com/eu/news/x4-pharmaceuticals-ema-chmp-positive-opinion-mavorixafor 2026-06-04T04:14:55.425Z NovaPharmaNews en 2026-06-03T16:43:07.991Z X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome Mavorixafor, WHIM Syndrome https://novapharmanews.com/uploads/articles/x4-pharmaceuticals-ema-chmp-positive-opinion-mavorixafor.webp X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome https://novapharmanews.com/us/news/fda-declines-guidance-foreign-drug-imports 2026-06-04T09:00:55.834Z NovaPharmaNews en 2026-06-03T16:07:48.130Z FDA Declines Guidance on Foreign Drug Imports: Impact on Pharma BD and Investors https://novapharmanews.com/uploads/articles/fda-declines-guidance-foreign-drug-imports.webp FDA Declines Guidance on Foreign Drug Imports: Impact on Pharma BD and Investors https://novapharmanews.com/eu/news/privosegtor-ema-prime-optic-neuritis 2026-06-04T15:25:22.823Z NovaPharmaNews en 2026-06-03T16:04:42.681Z Privosegtor Secures EMA PRIME Designation for Optic Neuritis Treatment optic neuritis https://novapharmanews.com/uploads/articles/privosegtor-ema-prime-optic-neuritis.webp Privosegtor Secures EMA PRIME Designation for Optic Neuritis Treatment https://novapharmanews.com/eu/news/arrowhead-pharmaceuticals-positive-cardiometabolic-data-european-a 2026-06-04T12:24:21.792Z NovaPharmaNews en 2026-06-03T15:44:55.661Z Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting Cardiometabolic disorders https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-positive-cardiometabolic-data-european-a.webp Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting https://novapharmanews.com/eu/news/teva-olan-ema-acceptance 2026-06-04T04:14:41.416Z NovaPharmaNews en 2026-06-03T15:33:17.329Z Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma Olan https://novapharmanews.com/uploads/articles/teva-olan-ema-acceptance.webp Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma https://novapharmanews.com/eu/news/florian-lordick-esmo-president-2026-elections-open 2026-06-04T11:11:47.341Z NovaPharmaNews en 2026-06-03T15:30:06.756Z Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology oncology https://novapharmanews.com/uploads/articles/florian-lordick-elected-2026-esmo-president-implications-for-global-oncology.webp Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology https://novapharmanews.com/us/news/ophthalmology-pipeline-milestones-q2-2026 2026-06-04T14:57:43.900Z NovaPharmaNews en 2026-06-03T14:03:59.687Z Ophthalmology Pipeline Milestones for Q2 2026: Key Catalysts and Investor Insights ophthalmology https://novapharmanews.com/uploads/articles/ophthalmology-pipeline-milestones-q2-2026.webp Ophthalmology Pipeline Milestones for Q2 2026: Key Catalysts and Investor Insights https://novapharmanews.com/eu/news/ema-approves-novo-wegovy-weight-loss-drug 2026-06-04T04:14:39.919Z NovaPharmaNews en 2026-06-03T13:59:34.566Z EMA Approves Novo's Wegovy: A Game Changer in Weight Loss Novo, Wegovy, Game, Changer, Weight, Loss https://novapharmanews.com/uploads/articles/ema-approves-novo-s-wegovy-a-game-changer-in-weight-loss.webp EMA Approves Novo's Wegovy: A Game Changer in Weight Loss https://novapharmanews.com/us/news/vir-biotechnology-stock-board-reshuffle-governance-votes 2026-06-04T10:18:41.183Z NovaPharmaNews en 2026-06-03T13:46:17.526Z Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/uploads/articles/vir-biotechnology-stock-board-reshuffle-governance-votes.webp Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/apac/news/big-pharma-china-trials-scrutiny-oncology 2026-06-04T09:46:48.405Z NovaPharmaNews en 2026-06-03T13:41:04.136Z Big Pharma's China Oncology Trials: Navigating a Landscape of Reduced Scrutiny oncology https://novapharmanews.com/uploads/articles/big-pharma-china-trials-scrutiny-oncology.webp Big Pharma's China Oncology Trials: Navigating a Landscape of Reduced Scrutiny https://novapharmanews.com/apac/news/premia-lind-lind-asia-ai-clinical-trials 2026-06-04T08:46:15.839Z NovaPharmaNews en 2026-06-03T12:54:19.518Z PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trials with AI https://novapharmanews.com/uploads/articles/premia-lind-lind-asia-ai-clinical-trials.webp PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trials with AI https://novapharmanews.com/eu/news/definitive-trial-milestone-50-percent-recruitment 2026-06-04T14:58:51.052Z NovaPharmaNews en 2026-06-03T12:34:07.717Z DEFINITIVE Trial Milestone: 50% Recruitment Achieved oncology https://novapharmanews.com/uploads/articles/definitive-trial-milestone-50-recruitment-achieved.webp DEFINITIVE Trial Milestone: 50% Recruitment Achieved https://novapharmanews.com/apac/news/kissei-pharmaceutical-halts-tavneos-use-amid-deaths 2026-06-04T04:14:49.916Z NovaPharmaNews en 2026-06-03T12:29:04.104Z Kissei Pharmaceutical Halts Tavneos Use Amid Deaths Tavneos https://novapharmanews.com/uploads/articles/kissei-pharmaceutical-halts-tavneos-use-amid-deaths.webp Kissei Pharmaceutical Halts Tavneos Use Amid Deaths https://novapharmanews.com/us/news/strengths-and-limitations-of-real-world-data-from-electronic-health-records-and-92ed37a9 2026-06-04T04:14:34.906Z NovaPharmaNews en 2026-06-03T12:17:43.536Z Real-World Data from EHRs and Claims: Strengths, Limitations, and Regulatory Impact https://novapharmanews.com/uploads/articles/strengths-and-limitations-of-real-world-data-from-electronic-health-records-and-92ed37a9.webp Real-World Data from EHRs and Claims: Strengths, Limitations, and Regulatory Impact https://novapharmanews.com/us/news/the-common-fund-data-ecosystem-cfde-449d7791 2026-06-04T12:53:03.873Z NovaPharmaNews en 2026-06-03T12:13:10.842Z The Common Fund Data Ecosystem (CFDE) https://novapharmanews.com/uploads/articles/the-common-fund-data-ecosystem-cfde.webp The Common Fund Data Ecosystem (CFDE) https://novapharmanews.com/us/news/the-gross-to-net-squeeze-how-physician-led-patient-education-reduces-gtn-erosion-17169d71 2026-06-04T12:36:13.465Z NovaPharmaNews en 2026-06-03T12:06:39.089Z Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze https://novapharmanews.com/uploads/articles/the-gross-to-net-squeeze-how-physician-led-patient-education-reduces-gtn-erosion-17169d71.webp Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze https://novapharmanews.com/us/news/a-secure-and-intelligent-drug-delivery-model-integrating-neural-networks-with-bl-853eecb6 2026-06-04T17:11:39.490Z NovaPharmaNews en 2026-06-03T11:58:42.851Z A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain https://novapharmanews.com/uploads/articles/a-secure-and-intelligent-drug-delivery-model-integrating-neural-networks-with-blockchain.webp A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain https://novapharmanews.com/us/news/the-market-for-monoclonal-antibodies-trends-challenges-and-opportunities-7a342d06 2026-06-03T13:00:59.052Z NovaPharmaNews en 2026-06-03T11:51:33.317Z The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024 monoclonal antibody, mAb, chronic diseases, autoimmune diseases https://novapharmanews.com/uploads/articles/the-market-for-monoclonal-antibodies-trends-challenges-and-opportunities-7a342d06.webp The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024 https://novapharmanews.com/us/news/opinion-the-medical-billing-ai-arms-race-between-providers-and-insurance 2026-06-04T12:38:16.953Z NovaPharmaNews en 2026-06-03T11:24:02.375Z Opinion: The medical-billing AI arms race between providers and insurance https://novapharmanews.com/uploads/articles/opinion-the-medical-billing-ai-arms-race-between-providers-and-insurance.webp Opinion: The medical-billing AI arms race between providers and insurance https://novapharmanews.com/us/news/amish-healthcare-lessons-public-health 2026-06-04T15:19:28.854Z NovaPharmaNews en 2026-06-03T11:24:01.460Z Opinion: The Amish Way of Healthcare Offers Lessons for Public Health https://novapharmanews.com/uploads/articles/amish-healthcare-lessons-public-health.webp Opinion: The Amish Way of Healthcare Offers Lessons for Public Health https://novapharmanews.com/us/news/nih-funding-cuts-ebola-preparedness-global-health 2026-06-04T14:57:39.858Z NovaPharmaNews en 2026-06-03T11:24:00.343Z NIH Funding Cuts Hamper Ebola Preparedness and Global Health Security Ebola https://novapharmanews.com/uploads/articles/nih-funding-cuts-ebola-preparedness-global-health.webp NIH Funding Cuts Hamper Ebola Preparedness and Global Health Security https://novapharmanews.com/us/news/ultra-processed-food-policy-demands-escalate-researchers-cite-systemic-issues 2026-06-04T15:45:25.194Z NovaPharmaNews en 2026-06-03T11:23:59.543Z Ultra-Processed Food Policy Demands Escalate as Researchers Cite Systemic Issues https://novapharmanews.com/uploads/articles/ultra-processed-food-policy-demands-escalate-researchers-cite-systemic-issues.webp Ultra-Processed Food Policy Demands Escalate as Researchers Cite Systemic Issues https://novapharmanews.com/apac/news/pmda-approves-new-pharmaceuticals-medical-devices-whats-new 2026-06-04T04:14:35.407Z NovaPharmaNews en 2026-06-03T03:09:14.935Z PMDA Approves New Pharmaceuticals and Medical Devices: What's New https://novapharmanews.com/uploads/articles/pmda-approves-new-pharmaceuticals-medical-devices-whats-new.webp PMDA Approves New Pharmaceuticals and Medical Devices: What's New https://novapharmanews.com/eu/news/eu-trade-policy-china-pharma-analysis 2026-06-04T17:12:55.238Z NovaPharmaNews en 2026-06-03T03:03:08.551Z EU Bolsters Trade Defenses Against Chinese Imports: A Pharmaceutical Market Analysis https://novapharmanews.com/uploads/articles/eu-trade-policy-china-pharma-analysis.webp EU Bolsters Trade Defenses Against Chinese Imports: A Pharmaceutical Market Analysis https://novapharmanews.com/eu/news/ema-january-drug-approvals-2025 2026-06-04T05:42:59.988Z NovaPharmaNews en 2026-06-03T02:53:30.934Z EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams https://novapharmanews.com/uploads/articles/ema-january-drug-approvals-2025.webp EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams https://novapharmanews.com/eu/news/chmp-drug-approvals-analysis 2026-06-04T05:38:57.431Z NovaPharmaNews en 2026-06-03T02:48:00.650Z CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry https://novapharmanews.com/uploads/articles/chmp-drug-approvals-analysis.webp CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry https://novapharmanews.com/us/news/munck-wilson-mandala-fort-worth-life-sciences-expansion 2026-06-04T14:49:47.887Z NovaPharmaNews en 2026-06-03T02:44:01.027Z Munck Wilson Mandala Expands to Fort Worth, Taps Life Sciences Leader https://novapharmanews.com/uploads/articles/munck-wilson-mandala-fort-worth-life-sciences-expansion.webp Munck Wilson Mandala Expands to Fort Worth, Taps Life Sciences Leader https://novapharmanews.com/us/news/fulcrum-therapeutics-stock-plunges-sickle-cell-drug-discontinuation 2026-06-04T13:40:56.776Z NovaPharmaNews en 2026-06-03T02:40:41.950Z Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation sickle cell disease https://novapharmanews.com/uploads/articles/fulcrum-therapeutics-stock-plunges-sickle-cell-drug-discontinuation.webp Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation https://novapharmanews.com/us/news/senior-nih-scientist-research-fellow-charged-with-bringing-deactivated-mpox-virus-into-u-s 2026-06-04T18:05:00.341Z NovaPharmaNews en 2026-06-03T02:39:08.229Z Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S. mpox https://novapharmanews.com/uploads/articles/senior-nih-scientist-research-fellow-charged-with-bringing-deactivated-mpox-virus-into-u-s.webp Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S. https://novapharmanews.com/us/news/cambridge-biotech-merger-acquisition-market-analysis 2026-06-04T12:37:49.951Z NovaPharmaNews en 2026-06-03T02:37:12.765Z Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures sickle cell https://novapharmanews.com/uploads/articles/cambridge-biotech-merger-acquisition-market-analysis.webp Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures https://novapharmanews.com/us/news/outlook-therapeutics-lytenava-fda-resubmission-60-day-review 2026-06-03T15:43:35.228Z NovaPharmaNews en 2026-06-03T02:07:31.338Z Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review LYTENAVA https://novapharmanews.com/uploads/articles/outlook-therapeutics-lytenava-fda-resubmission-60-day-review.webp Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review https://novapharmanews.com/us/news/hanmi-signs-licensing-deal-lilly-sonefpeglutide 2026-06-04T12:26:55.574Z NovaPharmaNews en 2026-06-03T01:55:24.362Z Hanmi Signs Licensing Deal with Eli Lilly for Sonefpeglutide, Bolstering GLP-2 Pipeline sonefpeglutide https://novapharmanews.com/uploads/articles/hanmi-signs-licensing-deal-lilly-sonefpeglutide.webp Hanmi Signs Licensing Deal with Eli Lilly for Sonefpeglutide, Bolstering GLP-2 Pipeline https://novapharmanews.com/us/news/fda-final-guidance-pulmonary-tuberculosis-drug-development 2026-06-04T17:56:54.196Z NovaPharmaNews en 2026-06-03T01:49:47.494Z FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development pulmonary tuberculosis https://novapharmanews.com/uploads/articles/fda-final-guidance-pulmonary-tuberculosis-drug-development.webp FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development https://novapharmanews.com/us/news/stat-pharmalittle-lilly-340b-ebola-vaccine-funding 2026-06-04T15:21:43.455Z NovaPharmaNews en 2026-06-02T19:37:04.227Z STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More Ebola https://novapharmanews.com/uploads/articles/stat-pharmalittle-lilly-340b-ebola-vaccine-funding.webp STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More